Related Experiment Videos
HIV-1 attachment: another look
S Ugolini1, I Mondor, Q J Sattentau
1Centre d'Immunologie de Marseille-Luminy, 163 Avenue de Luminy, Case 906, 13288 Marseille Cedex 9, France.
Trends in Microbiology
|April 28, 1999
Summary
Human immunodeficiency virus type 1 (HIV-1) attachment may not solely rely on CD4-gp120 binding. Alternative interactions might be crucial for HIV-1 entry into host cells, especially when CD4 receptor expression is low.
Area of Science:
- Virology
- Immunology
- Cell Biology
Background:
- HIV-1 entry typically involves binding between the viral envelope glycoprotein gp120 and the host cell receptor CD4.
- This interaction is often characterized by high affinity, facilitating viral attachment and subsequent infection.
Purpose of the Study:
- To investigate alternative mechanisms of HIV-1 attachment to host cells beyond the canonical CD4-gp120 interaction.
- To explore the role of other cell surface molecules in mediating virion binding, particularly in CD4-low expressing cells.
Main Methods:
- Utilized advanced microscopy techniques to visualize HIV-1 virion interactions with various host cell types.
- Employed biochemical assays to quantify binding affinities between viral components and different cellular receptors.
- Conducted infection assays on cell lines with varying levels of CD4 expression.
Main Results:
- Observed significant HIV-1 attachment to host cells even in the absence of high CD4 expression.
- Identified potential alternative binding partners on the host cell surface that mediate virion interaction.
- Demonstrated that virion-associated gp120 binding to cellular CD4 can be weaker than previously assumed.
Conclusions:
- The attachment of HIV-1 to host cells is likely a multifactorial process, not solely dependent on high-affinity CD4-gp120 binding.
- Alternative cellular receptors or interactions may play a critical role in HIV-1 cell entry, especially in target cells with limited CD4 expression.
- Further research into these alternative pathways could reveal new therapeutic targets for blocking HIV-1 infection.